《新股消息》传微医最快下月申请在港上市 估值接近70亿美元
《彭博通讯社》引述知情人士报道,腾讯(00700.HK)有份投资的网上医疗平台微医正计划最快下个月申请在香港上市,而公司在最近一轮融资的估值为68亿美元。
据了解,微医在去年底的首次公开募股前中筹得约4亿美元。为了准备上市,公司将业务分拆成两部分,并计划将健康护理服务,包括线上及实地谘询业务上市,而涉及敏感个人医疗记录的数据业务则会保持私营,以符合法规要求。
对於其集资及上市计划的消息,微医拒绝就此作出评论。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.